Sorafenib, sunitinib may pose cardiovascular risk

October 13, 2015
Sorafenib, sunitinib may pose cardiovascular risk

(HealthDay)—Older kidney cancer patients treated with sorafenib or sunitinib may face an increased risk of cardiovascular adverse events, according to a study published online Oct. 6 in Cancer.

Sekwon Jang, M.D., from the Inova Dwight and Martha Schar Cancer Institute in Fairfax, Virginia, and colleagues used the Surveillance, Epidemiology, and End Results-Medicare database to identify patients who were 66 years or older and were diagnosed with (RCC) from 2000 to 2009. The incidence of cardiovascular adverse events was analyzed through December 2010.

The researchers found that 171 of 670 patients who received sunitinib or sorafenib had cardiovascular events. The incidence rates for and cardiomyopathy, , and stroke were 0.87, 0.14, and 0.14 per 1,000 person-days, respectively. There was an increased risk of cardiovascular events associated with sunitinib or sorafenib use (hazard ratio [HR], 1.38), especially for stroke (HR, 2.84), compared with the 788 patients diagnosed with advanced RCC from 2007 to 2009 who were eligible but did not receive either drug. Patients aged 66 to 74 years at diagnosis had the highest increased risk of stroke associated with use of the drugs.

"Sunitinib and sorafenib might be associated with an increased risk of and particularly stroke," conclude the authors.

Two authors report financial ties to the pharmaceutical industry.

Explore further: Nonalbuminuric CKD ups cardiovascular morbidity in T1DM

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Nonalbuminuric CKD ups cardiovascular morbidity in T1DM

August 31, 2015

(HealthDay)—Nonalbuminuric chronic kidney disease is associated with increased risk of cardiovascular disease and all-cause mortality, but not renal outcomes, in patients with type 1 diabetes, according to a study published ...

Anemia linked to adverse outcomes in atrial fibrillation

March 4, 2015

(HealthDay)—For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality, according to ...

Modest relation between HbA1c, cardiovascular events

September 4, 2015

(HealthDay)—For patients with type 2 diabetes, hemoglobin A1c (HbA1c) is not significantly associated with cardiovascular events, regardless of clinical manifestation of vascular disease, according to a study published ...

Recommended for you

Ancient stress response provides clues to cancer resistance

April 25, 2017

Cancer is often able to craftily outwit the best techniques modern medicine has developed to treat it. In an attempt to understand and combat cancer's vaunted prowess, an unusual collaboration between physicists and a leading ...

Studying a catalyst for blood cancers

April 25, 2017

Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.